pioglitazone has been researched along with Sensitivity and Specificity in 22 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 7.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients." | 6.47 | Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. ( Forst, T; Pfützner, A, 2011) |
| "Besides the effectiveness in blood sugar control, pioglitazone could salutarily reduce proteinuria and synthesis of TGF-beta as well as type IV collagen." | 5.12 | Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. ( Eiam-Ong, S; Katavetin, P; Suwanwalaikorn, S, 2006) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 3.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| " Average increases in insulin dosage with exenatide and placebo were 13 U/d and 20 U/d." | 2.76 | Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. ( Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J, 2011) |
| "Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients." | 2.47 | Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. ( Forst, T; Pfützner, A, 2011) |
| " DPP-4 inhibitors are safe and tolerable with no increased risk of adverse events compared to placebo and have a low risk of hypoglycaemia." | 2.45 | Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. ( Ahrén, B, 2009) |
| " The differences between the pharmacokinetic parameters Cmax, AUC0-24, AUC0-∞, CL/F of (+)-pioglitazone and (-)-pioglitazone were significant, suggesting that the disposition of pioglitazone in rats may be enantioselective." | 1.40 | Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats. ( Du, B; Pang, L; Shen, G; Yang, Y; Zhang, Z, 2014) |
| "The rapid, sensitive, and selective liquid chromatography-electrospray ionization-tandem mass spectrometry method (LC-ESI-MS/MS) for the simultaneous estimation and pharmacokinetic investigation of glimepiride and pioglitazone in human plasma has been developed and fully validated." | 1.40 | Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ( Hu, JQ; Ni, XJ; Qiu, C; Shang, DW; Wang, ZZ; Wen, YG; Zhang, M, 2014) |
| " The method is simple, selective, robust economic and has been applied successfully to more than 2000 plasma samples as part of pharmacokinetic study in humans." | 1.39 | Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ( Bharathi, DV; Jagadeesh, B; Narayana, VS; Pankaj, C; Venkateswarulu, V, 2013) |
| "Metformin was the antidiabetic drug at the highest concentration in wastewater and surface water (up to 253 ng L(-1) and 104 ng L(-1), respectively)." | 1.38 | High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples. ( Alonso, E; Aparicio, I; Buchberger, W; Martín, J; Santos, JL, 2012) |
| " Thus, the proposed method is simple and suitable for the simultaneous analysis of active ingredients in dosage forms and human serum." | 1.37 | Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC. ( Arayne, MS; Mirza, AZ; Sultana, N, 2011) |
| "A simple, precise, rapid, and reproducible reversed-phase high-performance liquid chromatography method is developed for the simultaneous estimation of metformin hydrochloride (MET), pioglitazone hydrochloride (PIO), and glimepiride (GLP) present in multicomponent dosage forms." | 1.35 | Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation. ( Amin, M; Jain, D; Jain, S, 2008) |
| " The assay has been applied successfully to a pharmacokinetic study with human volunteers." | 1.33 | High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. ( Neamhom, P; Saraphanchotiwitthaya, A; Sripalakit, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelani, KM | 1 |
| Rezk, MR | 1 |
| Badran, OM | 1 |
| Elghobashy, MR | 1 |
| Jagadeesh, B | 1 |
| Bharathi, DV | 1 |
| Pankaj, C | 1 |
| Narayana, VS | 1 |
| Venkateswarulu, V | 1 |
| Du, B | 1 |
| Pang, L | 1 |
| Yang, Y | 1 |
| Shen, G | 1 |
| Zhang, Z | 1 |
| Ni, XJ | 1 |
| Wang, ZZ | 1 |
| Shang, DW | 1 |
| Zhang, M | 1 |
| Hu, JQ | 1 |
| Qiu, C | 1 |
| Wen, YG | 1 |
| Kawaguchi-Suzuki, M | 1 |
| Bril, F | 1 |
| Sanchez, PP | 1 |
| Cusi, K | 1 |
| Frye, RF | 1 |
| Jain, D | 2 |
| Jain, S | 1 |
| Amin, M | 1 |
| Souri, E | 1 |
| Jalalizadeh, H | 1 |
| Saremi, S | 1 |
| Al-Arfaj, NA | 1 |
| Al-Abdulkareem, EA | 1 |
| Aly, FA | 1 |
| Ahrén, B | 1 |
| Zheng, ZH | 1 |
| Lu, XH | 1 |
| Zhang, H | 1 |
| Lv, GP | 1 |
| He, JG | 1 |
| Zhao, BH | 1 |
| Si, SY | 1 |
| Pfützner, A | 2 |
| Schöndorf, T | 1 |
| Hanefeld, M | 1 |
| Forst, T | 2 |
| Kume, O | 1 |
| Takahashi, N | 1 |
| Wakisaka, O | 1 |
| Nagano-Torigoe, Y | 1 |
| Teshima, Y | 1 |
| Nakagawa, M | 1 |
| Yufu, K | 1 |
| Hara, M | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Duffy, HS | 1 |
| Buse, JB | 1 |
| Bergenstal, RM | 1 |
| Glass, LC | 1 |
| Heilmann, CR | 1 |
| Lewis, MS | 1 |
| Kwan, AY | 1 |
| Hoogwerf, BJ | 1 |
| Rosenstock, J | 1 |
| Arayne, MS | 1 |
| Sultana, N | 1 |
| Mirza, AZ | 1 |
| Martín, J | 1 |
| Buchberger, W | 1 |
| Santos, JL | 1 |
| Alonso, E | 1 |
| Aparicio, I | 1 |
| Xue, YJ | 1 |
| Turner, KC | 1 |
| Meeker, JB | 1 |
| Pursley, J | 1 |
| Arnold, M | 1 |
| Unger, S | 1 |
| Kolte, BL | 1 |
| Raut, BB | 1 |
| Deo, AA | 1 |
| Bagool, MA | 1 |
| Shinde, DB | 1 |
| Katavetin, P | 1 |
| Eiam-Ong, S | 1 |
| Suwanwalaikorn, S | 1 |
| Sripalakit, P | 1 |
| Neamhom, P | 1 |
| Saraphanchotiwitthaya, A | 1 |
| Radhakrishna, T | 1 |
| Sreenivas Rao, D | 1 |
| Om Reddy, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications[NCT00765817] | Phase 3 | 261 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in body weight following 30 weeks of therapy (i.e., body weight at week 30 minus body weight at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | kg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.78 |
| Placebo Arm | 0.96 |
Change in daily insulin dose following 30 weeks of therapy (i.e., daily insulin dose at week 30 minus daily insulin dose at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | insulin units (U) (Least Squares Mean) |
|---|---|
| Exenatide Arm | 13.19 |
| Placebo Arm | 19.71 |
Change in daily insulin dose per kilogram (kg) following 30 weeks of therapy (i.e., daily insulin dose per kg at week 30 minus daily insulin dose per kg at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | insulin units per kg (U/kg) (Least Squares Mean) |
|---|---|
| Exenatide Arm | 0.15 |
| Placebo Arm | 0.20 |
Change in DBP following 30 weeks of therapy (i.e., DBP at week 30 minus DBP at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.73 |
| Placebo Arm | 1.69 |
Change in fasting serum glucose following 30 weeks of therapy (i.e., fasting serum glucose at week 30 minus fasting serum glucose at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.28 |
| Placebo Arm | -0.87 |
Change in HbA1c from baseline following 30 weeks of therapy (i.e., HbA1c at week 30 minus HbA1c at baseline). Unit of measure is percent of hemoglobin that is glycosylated. (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage of hemoglobin (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.71 |
| Placebo Arm | -1.00 |
Change in HDL cholesterol following 30 weeks of therapy (i.e., HDL cholesterol at week 30 minus HDL cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | 0.01 |
| Placebo Arm | 0.00 |
Change in LDL cholesterol following 30 weeks of therapy (i.e., LDL cholesterol at week 30 minus LDL cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.19 |
| Placebo Arm | -0.00 |
Change in SBP following 30 weeks of therapy (i.e., SBP at week 30 minus SBP at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Exenatide Arm | -2.74 |
| Placebo Arm | 1.71 |
Change in total cholesterol following 30 weeks of therapy (i.e., total cholesterol at week 30 minus total cholesterol at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.16 |
| Placebo Arm | -0.02 |
Change in triglycerides following 30 weeks of therapy (i.e., triglycerides at week 30 minus triglycerides at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Arm | -0.02 |
| Placebo Arm | -0.03 |
Change in waist circumference following 30 weeks of therapy (i.e., waist circumference at week 30 minus waist circumference at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| Exenatide Arm | -1.08 |
| Placebo Arm | -0.25 |
Number of minor hypoglycemia events experienced per subject per year. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL). (NCT00765817)
Timeframe: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30
| Intervention | events per subject per year (Mean) |
|---|---|
| Exenatide Arm | 1.61 |
| Placebo Arm | 1.55 |
Percentage of patients in each arm who had HbA1c >6.5% at baseline and had HbA1c <=6.5% at week 30 (percentage = [number of subjects with HbA1c <=6.5% at week 30 divided by number of subjects with HbA1c >6.5% at baseline] * 100%). (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 42.0 |
| Placebo Arm | 13.3 |
Percentage of patients in each arm who had HbA1c >7% at baseline and had HbA1c <=7% at week 30 (percentage = [number of subjects with HbA1c <=7% at week 30 divided by number of subjects with HbA1c >7% at baseline] * 100%). (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 58.3 |
| Placebo Arm | 31.1 |
Percentage of subjects in each arm experiencing at least one episode of minor hypoglycemia at any point during the study. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL). (NCT00765817)
Timeframe: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30
| Intervention | percentage (Number) |
|---|---|
| Exenatide Arm | 24.8 |
| Placebo Arm | 28.7 |
Change in 7-point (pre-breakfast, 2 hour post-breakfast, pre-lunch, 2 hour post-lunch, pre-dinner, 2 hour post-dinner, 0300 hours) SMBG profile from baseline to week 30 (change = blood glucose value at week 30 minus blood glucose value at baseline) (NCT00765817)
Timeframe: baseline and 30 weeks
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-breakfast: baseline | Pre-breakfast: change at week 30 | 2 hour post-breakfast: baseline | 2 hour post-breakfast: change at week 30 | Pre-lunch: baseline | Pre-lunch: change at week 30 | 2 hour post-lunch: baseline | 2 hour post-lunch: change at week 30 | Pre-dinner: baseline | Pre-dinner: change at week 30 | 2 hour post-dinner: baseline | 2 hour post-dinner: change at week 30 | 0300: baseline | 0300: change at week 30 | |
| Exenatide Arm | 7.89 | -1.58 | 10.89 | -3.56 | 8.95 | -2.23 | 11.35 | -2.74 | 9.85 | -2.25 | 12.03 | -3.87 | 8.95 | -2.27 |
| Placebo Arm | 8.27 | -1.48 | 11.82 | -1.72 | 9.77 | -1.15 | 11.70 | -1.38 | 9.99 | -1.33 | 11.86 | -1.34 | 9.20 | -1.48 |
3 reviews available for pioglitazone and Sensitivity and Specificity
| Article | Year |
|---|---|
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptid | 2009 |
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Humans; | 2010 |
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.
Topics: Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Pr | 2011 |
2 trials available for pioglitazone and Sensitivity and Specificity
| Article | Year |
|---|---|
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Dru | 2011 |
Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-R | 2006 |
17 other studies available for pioglitazone and Sensitivity and Specificity
| Article | Year |
|---|---|
Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Linear Models; Pioglitazone; Piperidines; Reproducibility of Results | 2019 |
Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Male; Metformin; Pioglitazone; Reproducibility of Re | 2013 |
Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Female; Linear Models; Male; Pioglita | 2014 |
Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Adult; Chromatography, High Pressure Liquid; Humans; Linear Models; Male; Pioglitazone; Reproducibil | 2014 |
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Linear Models; Non-alcoholic Fatt | 2014 |
Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Pioglitazone; Reference Standa | 2008 |
Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Male; Pioglitazone; Reproducibility of | 2008 |
Flow-injection chemiluminometric determination of pioglitazone HCl by its sensitizing effect on the cerium-sulfite reaction.
Topics: Cerium; Flow Injection Analysis; Luminescent Measurements; Molecular Structure; Oxidation-Reduction; | 2009 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa | 2010 |
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc | 2011 |
Inflammatory responses in the atria: should they stay or should they go?
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat | 2011 |
Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Glyburide; Humans; Linear Model | 2011 |
High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.
Topics: Chromatography, High Pressure Liquid; Drinking Water; Glyburide; Hydrogen-Ion Concentration; Hypogly | 2012 |
Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Pioglitazone; Reprod | 2003 |
Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Hypoglycemic Agents; Metformin; Pharmaceutical P | 2004 |
High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Pioglitazone; Reproducibility of Resul | 2006 |
Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods.
Topics: Chromatography, High Pressure Liquid; Chromatography, Micellar Electrokinetic Capillary; Drug Contam | 2002 |